Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
dc.contributor.author | Santos, Igor de Andrade | |
dc.contributor.author | Grosche, Victoria Riquena [UNESP] | |
dc.contributor.author | Goulart Bergamini, Fernando Rodrigues | |
dc.contributor.author | Sabino-Silva, Robinson | |
dc.contributor.author | Gomes Jardim, Ana Carolina [UNESP] | |
dc.contributor.institution | Universidade Federal de Uberlândia (UFU) | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2020-12-10T17:59:17Z | |
dc.date.available | 2020-12-10T17:59:17Z | |
dc.date.issued | 2020-08-13 | |
dc.description.abstract | Coronaviruses (CoVs) are a group of viruses from the familyCoronaviridaethat can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as havingin vitroand/orin vivoantiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates. | en |
dc.description.affiliation | Univ Fed Uberlandia, Inst Biomed Sci, Lab Virol, Uberlandia, MG, Brazil | |
dc.description.affiliation | Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, Brazil | |
dc.description.affiliation | Univ Fed Uberlandia, Inst Chem, Lab Synth Bioinspired Mol, Uberlandia, MG, Brazil | |
dc.description.affiliation | Univ Fed Uberlandia, Inst Biomed Sci, Dept Physiol, Uberlandia, MG, Brazil | |
dc.description.affiliationUnesp | Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, Brazil | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) | |
dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.description.sponsorship | FAU/UFU | |
dc.description.sponsorshipId | FAPEMIG: APQ-00587-14 -SICONV 793988/2013 | |
dc.description.sponsorshipId | FAPEMIG: APQ-02872-16 | |
dc.description.sponsorshipId | FAPEMIG: APQ-03385-18 | |
dc.description.sponsorshipId | CAPES: 1678329P | |
dc.description.sponsorshipId | CNPq: 311219/2019-5 | |
dc.description.sponsorshipId | CNPq: CNPq465669/2014-0 | |
dc.description.sponsorshipId | CAPES: CNPq465669/2014-0 | |
dc.description.sponsorshipId | FAPEMIG: CNPq465669/2014-0 | |
dc.description.sponsorshipId | CAPES: 88881.506794/2020-01 | |
dc.format.extent | 23 | |
dc.identifier | http://dx.doi.org/10.3389/fmicb.2020.01818 | |
dc.identifier.citation | Frontiers In Microbiology. Lausanne: Frontiers Media Sa, v. 11, 23 p., 2020. | |
dc.identifier.doi | 10.3389/fmicb.2020.01818 | |
dc.identifier.issn | 1664-302X | |
dc.identifier.uri | http://hdl.handle.net/11449/195658 | |
dc.identifier.wos | WOS:000565985000001 | |
dc.language.iso | eng | |
dc.publisher | Frontiers Media Sa | |
dc.relation.ispartof | Frontiers In Microbiology | |
dc.source | Web of Science | |
dc.subject | antivirals | |
dc.subject | coronaviruses | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | treatment | |
dc.title | Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? | en |
dc.type | Resenha | |
dcterms.rightsHolder | Frontiers Media Sa |